Advent to acquire 50.1% stake in Suven Pharma
Advent International will acquire a 50.1% stake in Suven Pharmaceuticals for about Rs 6,300 crore, with an aim to merge the drugmaker with a portfolio company, Cohance Lifesciences. The merger of Cohance with Suven would help in building a leading Clinical Drug Development and Manufacturing (CDMO) and merchant Active Pharmaceutical Ingredient (API) player, servicing the pharma and specialty chemical markets....